 there are no data demonstrating that
reducing homocysteine serum levels decreases the likelihood
of adverse cardiovascular events in patients with PAD,87
although clinical trials are ongoing.87-89 Pending the outcomes of prospective trials, treating hyperhomocysteinemia
with folic acid to reduce serum levels to <10 mmol/L is
generally safe and well tolerated but is of no proven beneï¬t.
4B. Pharmacotherapy for patients with IC